Workboat Indexes

Markets:

Overview

News

Currencies

International

Treasuries

Bristol-Myers Squibb (NY:BMY)

54.65 -0.06 (-0.11%)

Streaming Delayed Price Updated: 10:49 AM EST, Dec 26, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9

...

84 85 Next >

3 Value Stocks with Warning Signs

October 09, 2025

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are...

Via StockStory

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Offers a High Dividend Yield and Strong Profitability ↗

October 08, 2025

Bristol Myers Squibb (BMY) offers a high 5.42% dividend yield with strong profitability and a decade of consistent payouts, making it a top stock for income investors.

Via Chartmill

BRISTOL-MYERS SQUIBB CO (NYSE:BMY) Presents a Strong Value Investment Case ↗

October 06, 2025

Bristol-Myers Squibb (BMY) offers strong value with a low P/E ratio, high profitability, and a solid 5.4% dividend yield, presenting a compelling case for value investors.

Via Chartmill

Price Over Earnings Overview: Bristol-Myers Squibb ↗

October 02, 2025

Via Benzinga

These 3 Pharma Stocks Are Rallying – And Still Trade Absurdly Cheap ↗

October 02, 2025

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

Via Benzinga

Bristol Myers To Sell Plaque Psoriasis Drug For Over 80% Discount Starting In 2026 ↗

September 25, 2025

Via Stocktwits

Bristol Myers Announces Positive Outcomes From Multiple Myeloma Late-Stage Study ↗

September 23, 2025

Via Stocktwits

What's going on in today's session: S&P500 movers ↗

October 02, 2025

Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Thursday.

Via Chartmill

Nanobiotix Stock Soars on Breakthrough Esophageal Cancer Data, Igniting Biotech Hopes

October 02, 2025

Paris, France – October 2, 2025 – Nanobiotix (NASDAQ: NBTX) witnessed a significant surge in its stock price today, jumping 11.6%, following the announcement of highly encouraging initial data from a...

Via MarketMinute

Healthcare Sector Defies Headwinds, Rallies on Wall Street Amidst Shutdown and Jobs Data

October 01, 2025

New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government...

Via MarketMinute

In today's session, there are S&P500 stocks with remarkable trading volume. ↗

October 01, 2025

In today's session, there are S&P500 stocks with remarkable trading volume. Explore the stocks exhibiting unusual volume in Wednesday's session.

Via Chartmill

Health Care Stocks Rally, Nike Beats The Street: What's Moving Markets Wednesday? ↗

October 01, 2025

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps markets afloat.

Via Benzinga

Why Is Bristol-Myers Squibb (BMY) Stock Rocketing Higher Today

October 01, 2025

Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 5.5% in the afternoon session after the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to its...

Via StockStory

Topics Artificial Intelligence

Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 4% Dividend Yields ↗

October 01, 2025

Via Benzinga

Bristol Myers Squibb’s Anti-MTBR-Tau-Targeting Antibody, BMS-986446, Granted Fast Track Designation by U.S. FDA for the Treatment of Alzheimer’s Disease

October 01, 2025

From Bristol Myers Squibb

Via Business Wire

Pharmaceutical Stocks Soar as White House Unveils Drug-Pricing Agreement, AbbVie Leads the Charge

September 30, 2025

Washington D.C. – September 30, 2025 – The pharmaceutical sector experienced a significant upward surge today, notably led by AbbVie (NYSE: ABBV), following reports of a groundbreaking drug-pricing...

Via MarketMinute

Topics Economy Government World Trade

Trump's Plan To Lower U.S. Drug Prices Faces Big Test ↗

September 30, 2025

But Trump might get less than he bargained for as drugmakers focus on prices abroad, rather than stateside efforts.

Via Investor's Business Daily

Topics Government

Merus N.V. Soars on $8 Billion Genmab Acquisition, Propelled by Oncology Pipeline Successes

September 29, 2025

Merus N.V. (NASDAQ: MRUS) has become the undisputed top performer in today's market, with its stock price rocketing by an astounding 35.9% following the bombshell announcement of its acquisition by...

Via MarketMinute

Pharma Lobby Announces New Website To Connect Patients With Manufacturer-Direct Purchase Program ↗

September 29, 2025

The announcement from the group coincides with the deadline set by President Trump for 17 pharmaceutical companies to reduce drug prices in the U.S. to the levels paid by other developed countries.

Via Stocktwits

Topics Government

Johnson & Johnson's Hypothetical Rally: A Look at Potential 2025 Valuation Drivers

September 27, 2025

In a hypothetical scenario playing out just last week, leading up to September 27, 2025, Johnson & Johnson (NYSE: JNJ) experienced a significant stock rally, capturing the attention of investors and...

Via MarketMinute

Topics Economy Intellectual Property

Immuneering Corporation's Stock Takes a Hit Amidst Funding Round Despite Promising Clinical Data

September 27, 2025

Boston, MA – September 27, 2025 – Immuneering Corporation (NASDAQ: IMRX) experienced a significant downturn in its stock value on September 25, 2025, with shares declining by approximately 13.3%. This...

Via MarketMinute

Trump's 100% Drug Tariffs 'A Meaningful Commercial Hit' For Americans, But 'Loopholes' Could Blunt Impact, Says Analyst ↗

September 26, 2025

President Donald Trump‘s proposed 100% tariffs on pharmaceuticals could have a smaller impact than initially expected, thanks to certain loopholes. However, the pharmaceutical industry, particularly...

Via Benzinga

Topics Government World Trade

Global Markets Brace for Impact as New U.S. Tariffs Escalate Trade Tensions Amidst Geopolitical Volatility

September 26, 2025

September 26, 2025 – Global financial markets are once again in the throes of uncertainty as the United States unveils a fresh wave of substantial trade tariffs, set to take effect on October 1, 2025....

Via MarketMinute

Topics Artificial Intelligence Economy Emissions

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Bristol Myers Squibb Builds on Eliquis® (apixaban) Direct-to-Patient Program, Announces New BMS Patient Connect Platform Offering Sotyktu® (deucravacitinib)

September 25, 2025

From Bristol Myers Squibb

Via Business Wire

The Smartest Dividend Stock to Buy With $1,000 Right Now ↗

September 24, 2025

Drug makers are out of favor right now, but the industry will survive. Here's one company that stands out as an investment option.

Via The Motley Fool

Topics Intellectual Property

Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? ↗

September 24, 2025

Pfizer has a huge yield right now, but it might make more sense for dividend investors to step down in yield to these two alternatives.

Via The Motley Fool

Topics Intellectual Property

Bristol Myers Squibb Franchise Gains Momentum With Phase 3 Results In Multiple Myeloma Patients ↗

September 23, 2025

Bristol Myers Squibb reported positive Phase 3 results for iberdomide in multiple myeloma; analysts eye CELMoDs as key to future growth.

Via Benzinga

Bristol Myers Squibb Announces Phase 3 EXCALIBER-RRMM Study Evaluating Iberdomide in Combination with Standard Therapies Demonstrated a Significant Improvement in Minimal Residual Disease Negativity Rates in Relapsed or Refractory Multiple Myeloma

September 23, 2025

From Bristol Myers Squibb

Via Business Wire

1 Reason to Buy Bristol Myers Squibb Stock ↗

September 23, 2025

Find out why investors seeking passive income want shares of this dividend payer in their portfolio.

Via The Motley Fool

Topics Intellectual Property

< Previous 1 2 3 4 5 6 7 8 9

...

84 85 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Workboat Indexes

Bristol-Myers Squibb (NY:BMY)

All News about Bristol-Myers Squibb

Groundbreaking held for Bayonne ferry terminal

Coast Guard to restore full operations at its Pascagoula station

Uncrewed ships coming to an ocean near you

Harbour to enter US Gulf through $3.2 billion LLOG acquisition